Literature DB >> 24239846

Evaluation of CXCL8, CXCL10, CXCL11, CXCL12 and CXCL13 in serum and cerebrospinal fluid of patients with neuroborreliosis.

Anna Moniuszko1, Piotr Czupryna2, Sławomir Pancewicz2, Krzysztof Rutkowski3, Olga Zajkowska4, Renata Swierzbińska2, Sambor Grygorczuk2, Maciej Kondrusik2, Piotr Owłasiuk5, Joanna Zajkowska2.   

Abstract

PURPOSE: Knowledge of the role of chemokines in the inflammation during neuroborreliosis (NB) is limited. We evaluated the pre- and post-treatment concentration of CXCL8, CXCL10, CXCL11, CXCL12, and CXCL13 in serum (s) and cerebrospinal fluid (csf) in patients with NB.
RESULTS: There was a statistically significant increase in pre-treatment s CXCL8, CXCL10, CXCL11, CXCL12, CXCL13 and csf CXCL8, CXCL11, CXCL12, CXCL13 in patients with early form of NB. CXCL8, CXCL11, CXCL12 and CXCL13 increase was the highest in csf. After treatment, a significant decrease in csf chemokine levels (except CXCL10) and s levels (except CXCL11) was observed.
CONCLUSIONS: CXCL8, CXCL10, CXCL11, CXCL12, CXCL13 are involved in the pathomechanism of NB but their role is different in s and csf. CXCL13 seems to be a good biomarker for NB. In early NB, it may facilitate the diagnosis and monitoring of therapy. However tick-borne encephalitis needs to be excluded as it also increases chemokine concentration. Decrease in all examined chemokines in s and csf after treatment suggests that chemokines may be useful in monitoring response to NB therapy.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CXCL10; CXCL11; CXCL12; CXCL13; CXCL8; Neuroborreliosis

Mesh:

Substances:

Year:  2013        PMID: 24239846     DOI: 10.1016/j.imlet.2013.11.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  6 in total

1.  Longitudinal Transcriptome Analysis Reveals a Sustained Differential Gene Expression Signature in Patients Treated for Acute Lyme Disease.

Authors:  Jerome Bouquet; Mark J Soloski; Andrea Swei; Chris Cheadle; Scot Federman; Jean-Noel Billaud; Alison W Rebman; Beniwende Kabre; Richard Halpert; Meher Boorgula; John N Aucott; Charles Y Chiu
Journal:  MBio       Date:  2016-02-12       Impact factor: 7.867

2.  Common and uncommon neurological manifestations of neuroborreliosis leading to hospitalization.

Authors:  Philipp Schwenkenbecher; Refik Pul; Ulrich Wurster; Josef Conzen; Kaweh Pars; Hans Hartmann; Kurt-Wolfram Sühs; Ludwig Sedlacek; Martin Stangel; Corinna Trebst; Thomas Skripuletz
Journal:  BMC Infect Dis       Date:  2017-01-21       Impact factor: 3.090

3.  CXCL13 chemokine as a promising biomarker to diagnose neurosyphilis in HIV-negative patients.

Authors:  Yan-Li Zeng; Yi-Qiang Lin; Ning-Ning Zhang; Chao-Ning Zou; Hui-Lin Zhang; Feng Peng; Zhao-Ji Liu; Wei-Hong Zheng; Jiang-Hua Yan; Li-Li Liu
Journal:  Springerplus       Date:  2016-06-16

4.  Cerebrospinal fluid cytokines in Lyme neuroborreliosis.

Authors:  Annukka Pietikäinen; Mikael Maksimow; Tommi Kauko; Saija Hurme; Marko Salmi; Jukka Hytönen
Journal:  J Neuroinflammation       Date:  2016-10-18       Impact factor: 8.322

Review 5.  Chemokine Ligand 13 (CXCL13) in Neuroborreliosis and Neurosyphilis as Selected Spirochetal Neurological Diseases: A Review of Its Diagnostic Significance.

Authors:  Monika Gudowska-Sawczuk; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

6.  Comparison of regulatory networks of E74-like factor 1 and cold-shock domain-containing E1 in breast cancer cell lines using ChIP datasets.

Authors:  Haibo Duan; Huafang He; Qian Hu; Yingxin Lin; Shuo Cao; Xiaoshan Lan; Litao Li; Danmei Pang
Journal:  Exp Ther Med       Date:  2020-10-22       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.